Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women.

Trial Profile

Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Carbomer polymer gel; PRO 2000
  • Indications HIV infections; Sexually transmitted infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2012 Actual end date changed from Nov 2011 to Sep 2008 as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Actual end date changed from Nov 2011 to Sep 2008 as reported by ClinicalTrials.gov.
    • 16 Feb 2011 Primary endpoint 'Seroconversion-rate' has not been met
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top